Cancer Cell,
Journal Year:
2024,
Volume and Issue:
42(5), P. 759 - 779.e12
Published: May 1, 2024
The
lack
of
comprehensive
diagnostics
and
consensus
analytical
models
for
evaluating
the
status
a
patient's
immune
system
has
hindered
wider
adoption
immunoprofiling
treatment
monitoring
response
prediction
in
cancer
patients.
To
address
this
unmet
need,
we
developed
an
platform
that
uses
multiparameter
flow
cytometry
to
characterize
cell
heterogeneity
peripheral
blood
healthy
donors
patients
with
advanced
cancers.
Using
unsupervised
clustering,
identified
five
immunotypes
unique
distributions
different
types
gene
expression
profiles.
An
independent
analysis
17,800
open-source
transcriptomes
same
approach
corroborated
these
findings.
Continuous
immunotype-based
signature
scores
were
correlate
systemic
immunity
patient
responses
treatments,
including
immunotherapy,
prognostically
predictively.
Our
findings
illustrate
potential
utility
simple
test
as
flexible
tool
stratifying
into
therapy
groups
based
on
immunoprofiling.
Nano-Micro Letters,
Journal Year:
2020,
Volume and Issue:
12(1)
Published: July 5, 2020
Abstract
Although
notable
progress
has
been
made
on
novel
cancer
treatments,
the
overall
survival
rate
and
therapeutic
effects
are
still
unsatisfactory
for
patients.
Chemoimmunotherapy,
combining
chemotherapeutics
immunotherapeutic
drugs,
emerged
as
a
promising
approach
treatment,
with
advantages
of
cooperating
two
kinds
treatment
mechanism,
reducing
dosage
drug
enhancing
effect.
Moreover,
nano-based
delivery
system
(NDDS)
was
applied
to
encapsulate
chemotherapeutic
agents
exhibited
outstanding
properties
such
targeted
delivery,
tumor
microenvironment
response
site-specific
release.
Several
nanocarriers
have
approved
in
clinical
chemotherapy
showed
significant
improvement
efficiency
compared
traditional
formulations,
liposomes
(Doxil
®
,
Lipusu
),
nanoparticles
(Abraxane
)
micelles
(Genexol-PM
).
The
applications
NDDS
chemoimmunotherapy
would
be
powerful
strategy
future
which
could
greatly
enhance
efficacy,
reduce
side
optimize
outcomes
Herein,
current
approaches
immunotherapy
were
discussed,
recent
advances
further
reviewed.
Exploration,
Journal Year:
2021,
Volume and Issue:
1(3)
Published: Dec. 1, 2021
Bioactive
materials
are
a
kind
of
with
unique
bioactivities,
which
can
change
the
cellular
behaviors
and
elicit
biological
responses
from
living
tissues.
came
into
spotlight
in
late
1960s
when
researchers
found
that
such
as
bioglass
could
react
surrounding
bone
tissue
for
regeneration.
In
following
decades,
advances
nanotechnology
brought
new
development
opportunities
to
bioactive
nanomaterials.
nanomaterials
not
simple
miniaturization
macroscopic
materials.
They
exhibit
bioactivities
due
their
nanoscale
size
effect,
high
specific
surface
area,
precise
nanostructure,
significantly
influence
interactions
systems.
Nowadays,
have
represented
an
important
exciting
area
research.
Current
future
applications
ensure
academic
clinical
importance.
This
review
summaries
recent
field
nanomaterials,
evaluate
factors
bioactivities.
Then,
range
potential
biomedical
discussed.
Furthermore,
limitations,
challenges,
also
Journal of Immunology Research,
Journal Year:
2020,
Volume and Issue:
2020, P. 1 - 13
Published: Nov. 17, 2020
Until
now,
three
types
of
well-recognized
cancer
treatments
have
been
developed,
i.e.,
surgery,
chemotherapy,
and
radiotherapy;
these
either
remove
or
directly
attack
the
cells.
These
can
cure
at
earlier
stages
but
are
frequently
ineffective
for
treating
in
advanced
recurrent
stages.
Basic
clinical
research
on
tumor
microenvironment,
which
consists
cancerous,
stromal,
immune
cells,
demonstrates
critical
role
antitumor
immunity
development
progression.
Cancer
immunotherapies
proposed
as
fourth
treatment.
In
particular,
application
checkpoint
inhibitors,
such
anti-CTLA-4
anti-PD-1/PD-L1
antibodies,
various
represents
a
major
breakthrough
therapy.
Nevertheless,
accumulating
data
regarding
inhibitors
demonstrate
that
not
always
effective
instead
only
limited
populations.
Indeed,
several
issues
remain
to
be
solved
improve
their
efficacy;
include
low
cell
antigenicity
poor
infiltration
and/or
accumulation
cells
microenvironment.
Therefore,
accelerate
further
immunotherapies,
more
studies
necessary.
this
review,
we
will
summarize
current
status
especially
vaccines,
discuss
potential
problems
solutions
next
immunotherapy.
Exploration,
Journal Year:
2022,
Volume and Issue:
2(3)
Published: March 15, 2022
Immunotherapy
strategies
that
use
cell-based
delivery
systems
have
sparked
much
interest
in
the
treatment
of
malignancies,
owing
to
their
high
biocompatibility,
excellent
tumor
targeting
capability,
and
unique
biofunctionalities
growth
process.
A
variety
design
principles
for
immunotherapy,
including
cell
surface
decoration,
membrane
coating,
encapsulation,
genetically
engineered
cell,
cell-derived
exosomes,
give
cancer
immunotherapy
great
potential
improve
therapeutic
efficacy
reduce
adverse
effects.
However,
methods
is
still
limited,
practical
uses
are
hampered
due
complex
physiological
immunological
obstacles,
such
as
physical
barriers
immune
infiltration,
immunosuppressive
microenvironment,
upregulation
pathways,
metabolic
restriction.
In
this
review,
we
present
an
overview
maximize
impact,
along
with
anatomical,
metabolic,
impediments
using
treat
cancer.
Following
that,
a
summary
novel
been
created
overcome
these
obstacles
immunotherapeutic
provided.
Also,
prospects
next-step
development
concluded
end.
Cancers,
Journal Year:
2023,
Volume and Issue:
15(7), P. 2116 - 2116
Published: April 1, 2023
Glioblastoma
multiforme
(GBM)
is
a
highly
aggressive
form
of
brain
cancer
that
difficult
to
treat
due
its
resistance
both
radiation
and
chemotherapy.
This
largely
the
unique
biology
GBM
cells,
which
can
evade
effects
conventional
treatments
through
mechanisms
such
as
increased
cell
death
rapid
regeneration
cancerous
cells.
Additionally,
blood–brain
barrier
makes
it
for
chemotherapy
drugs
reach
leading
reduced
effectiveness.
Despite
these
challenges,
there
are
several
treatment
options
available
GBM.
The
standard
care
newly
diagnosed
patients
involves
surgical
resection
followed
by
concurrent
chemoradiotherapy
adjuvant
Emerging
include
immunotherapy,
checkpoint
inhibitors,
targeted
therapies,
bevacizumab,
attempt
attack
specific
vulnerabilities
in
Another
promising
approach
use
tumor-treating
fields,
type
electric
field
therapy
has
been
shown
slow
growth
Clinical
trials
ongoing
evaluate
safety
efficacy
other
innovative
GBM,
intending
improve
with
outcomes
patients.
